IS7041A - 5-HT viðtakabindlar og notkun þeirra - Google Patents
5-HT viðtakabindlar og notkun þeirraInfo
- Publication number
- IS7041A IS7041A IS7041A IS7041A IS7041A IS 7041 A IS7041 A IS 7041A IS 7041 A IS7041 A IS 7041A IS 7041 A IS7041 A IS 7041A IS 7041 A IS7041 A IS 7041A
- Authority
- IS
- Iceland
- Prior art keywords
- receptors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29995301P | 2001-06-21 | 2001-06-21 | |
PCT/IB2002/002261 WO2003000663A1 (en) | 2001-06-21 | 2002-06-17 | 5-ht receptor ligands and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IS7041A true IS7041A (is) | 2003-11-17 |
Family
ID=23157027
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS7040A IS7040A (is) | 2001-06-21 | 2003-11-17 | 5-HT viðtakabindlar og notkun þeirra |
IS7041A IS7041A (is) | 2001-06-21 | 2003-11-17 | 5-HT viðtakabindlar og notkun þeirra |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS7040A IS7040A (is) | 2001-06-21 | 2003-11-17 | 5-HT viðtakabindlar og notkun þeirra |
Country Status (39)
Country | Link |
---|---|
US (6) | US6825198B2 (is) |
EP (2) | EP1401820A1 (is) |
JP (2) | JP2004534823A (is) |
KR (2) | KR100566854B1 (is) |
CN (2) | CN1630645A (is) |
AP (1) | AP2002002561A0 (is) |
AR (1) | AR036095A1 (is) |
AU (1) | AU2002309173B2 (is) |
BG (2) | BG108495A (is) |
BR (2) | BR0210471A (is) |
CA (2) | CA2450491A1 (is) |
CR (1) | CR7168A (is) |
CZ (2) | CZ20033431A3 (is) |
DO (1) | DOP2002000412A (is) |
EA (2) | EA007183B1 (is) |
EC (2) | ECSP034881A (is) |
EE (2) | EE200400026A (is) |
GE (1) | GEP20053655B (is) |
GT (1) | GT200200120A (is) |
HR (1) | HRP20031042A2 (is) |
HU (2) | HUP0400251A3 (is) |
IL (2) | IL158807A0 (is) |
IS (2) | IS7040A (is) |
MA (2) | MA27035A1 (is) |
MX (2) | MXPA03011940A (is) |
NO (2) | NO20035697D0 (is) |
NZ (1) | NZ529542A (is) |
OA (2) | OA12629A (is) |
PA (1) | PA8548901A1 (is) |
PE (1) | PE20030268A1 (is) |
PL (2) | PL367777A1 (is) |
SK (2) | SK15672003A3 (is) |
SV (1) | SV2003001102A (is) |
TN (2) | TNSN03143A1 (is) |
UA (1) | UA74443C2 (is) |
UY (1) | UY27343A1 (is) |
WO (2) | WO2003000666A1 (is) |
YU (1) | YU95303A (is) |
ZA (2) | ZA200308843B (is) |
Families Citing this family (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7354923B2 (en) * | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
AU2002331064B2 (en) * | 2001-08-10 | 2007-08-23 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
US7732451B2 (en) * | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
US7655658B2 (en) * | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
US7456184B2 (en) * | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
US7226925B2 (en) | 2002-06-19 | 2007-06-05 | Biovitrum Ab | Compounds, their use and preparation |
EP1513831B1 (en) | 2002-06-19 | 2010-01-06 | Biovitrum AB (publ) | Novel compounds, their use and preparation |
ATE374766T1 (de) | 2003-01-14 | 2007-10-15 | Arena Pharm Inc | 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
CA2514220C (en) * | 2003-01-29 | 2012-02-28 | Pharmagene Laboratories Limited | Ep4 receptor antagonists |
NZ541861A (en) | 2003-02-26 | 2009-05-31 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors |
US20080146583A1 (en) * | 2003-05-15 | 2008-06-19 | Pfizer Inc | Treatment of Incontinence |
US20040235856A1 (en) * | 2003-04-25 | 2004-11-25 | Pfizer Inc | Treatment of incontinence |
CL2004000826A1 (es) | 2003-04-25 | 2005-03-04 | Pfizer | Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 |
US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
US7968548B2 (en) | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
PL2332921T3 (pl) | 2003-06-17 | 2016-08-31 | Arena Pharm Inc | Chlorowodorek 8-chloro-1-metylo-2,3,4,5-tetrahydro-1H-3-benzazepiny |
EP2332920A3 (en) | 2003-06-17 | 2011-12-21 | Arena Pharmaceuticals, Inc. | Processes for preparing 3-benzazepines |
CA2529750A1 (en) * | 2003-06-20 | 2005-02-24 | Arena Pharmaceuticals, Inc. | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
AU2004257267B2 (en) | 2003-07-14 | 2009-12-03 | Arena Pharmaceuticals,Inc | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
MXPA06003615A (es) | 2003-09-30 | 2006-06-05 | Amgen Inc | Ligandos del receptor vanilloide y su uso en tratamientos. |
WO2005053688A1 (en) | 2003-11-26 | 2005-06-16 | Alcon, Inc. | Substituted furo[2,3-g] indazoles for the treatment of glaucoma |
US7338972B1 (en) | 2003-12-15 | 2008-03-04 | Alcon, Inc. | Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma |
EP1694670A1 (en) * | 2003-12-16 | 2006-08-30 | GPC Biotech AG | Pyrazine derivatives as effective compounds against infectious diseases |
WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
PT1756084E (pt) * | 2004-06-04 | 2009-02-17 | Arena Pharm Inc | Composto seleccionado de compostos de fórmula (i) e seus sais, solvatos, hidratos e n-óxidos farmaceuticamente aceitáveis |
EP2248524A3 (en) | 2004-08-25 | 2011-03-09 | Takeda Pharmaceutical Company Limited | Preventives/remedies for stress urinary incontinence and method of screening the same |
US8114502B2 (en) * | 2004-09-02 | 2012-02-14 | 3M Innovative Properties Company | Substrates with multiple images |
BRPI0518241A (pt) * | 2004-11-01 | 2008-04-22 | Amylin Pharmaceuticals Inc | métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade |
AU2005305036B2 (en) * | 2004-11-01 | 2011-03-10 | Amylin Pharmaceuticals, Llc | Treatment of obesity and related disorders |
US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
AR051946A1 (es) * | 2004-11-05 | 2007-02-21 | Wyeth Corp | Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina |
JP2008520713A (ja) | 2004-11-17 | 2008-06-19 | ミイカナ セラピューティクス インコーポレイテッド | キナーゼ阻害剤 |
WO2006064780A1 (ja) * | 2004-12-14 | 2006-06-22 | Shionogi & Co., Ltd. | 便秘治療剤 |
NZ555981A (en) | 2004-12-21 | 2011-01-28 | Arena Pharm Inc | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
NZ555482A (en) | 2004-12-23 | 2011-01-28 | Arena Pharm Inc | Compositions comprising a 5HT2C receptor modulator and 2-methylamphetamine and methods of use |
CA2595607C (en) * | 2005-01-25 | 2014-07-15 | Epix Delaware, Inc. | Substituted arylamine compounds and their use as 5-ht6 modulators |
AU2006228378A1 (en) * | 2005-03-31 | 2006-10-05 | Pfizer Products Inc. | Cyclopentapyridine and tetrahydroquinoline derivatives |
US7594976B2 (en) * | 2005-05-13 | 2009-09-29 | 3M Innovative Properties Company | Methods of manufacturing substrates |
JP2009502961A (ja) | 2005-07-29 | 2009-01-29 | コンサート ファーマシューティカルズ インコーポレイテッド | 新規な医薬組成物 |
KR20140025610A (ko) * | 2005-09-30 | 2014-03-04 | 미카나 테라퓨틱스, 인크. | 치환된 피라졸 화합물 |
PT1963302E (pt) * | 2005-12-05 | 2013-04-09 | Pfizer Prod Inc | Polimorfos de um inibidor de c-met/hgfr |
NZ568654A (en) * | 2005-12-05 | 2012-02-24 | Pfizer Prod Inc | Method of treating abnormal cell growth |
WO2007075555A2 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Combination of an h3 antagonist/inverse agonist and an appetite suppressant |
EP2471779A1 (en) | 2006-04-03 | 2012-07-04 | Arena Pharmaceuticals, Inc. | Process for the resolution of a mixture of (R)- and (S)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
EP2018863B9 (en) | 2006-05-16 | 2015-02-18 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound and use thereof |
CN101448820A (zh) * | 2006-05-30 | 2009-06-03 | 霍夫曼-拉罗奇有限公司 | 哌啶基嘧啶衍生物 |
WO2008010073A1 (en) * | 2006-07-14 | 2008-01-24 | Pfizer Products Inc. | Tartrate salt of (7s)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2r)-2-methylpiperazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine |
US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
AU2007320906A1 (en) | 2006-11-13 | 2008-05-22 | Pfizer Products Inc. | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof |
SI2848610T1 (en) * | 2006-11-15 | 2018-02-28 | Ym Biosciences Australia Pty Ltd | Inhibitors of kinase activity |
ES2522587T3 (es) | 2006-12-05 | 2014-11-17 | Arena Pharmaceuticals, Inc. | Procesos para preparar (R)-8-cloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzacepina e intermedios de la misma |
TWI440456B (zh) | 2007-01-16 | 2014-06-11 | 用於治療代謝性症候群之新穎化合物 | |
US20080220104A1 (en) * | 2007-03-08 | 2008-09-11 | Cappello John V | Compositions for producing satiety |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
EA020466B1 (ru) | 2007-06-04 | 2014-11-28 | Синерджи Фармасьютикалз Инк. | Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний |
JP2010529193A (ja) * | 2007-06-11 | 2010-08-26 | ミイカナ セラピューティクス インコーポレイテッド | 置換ピラゾール化合物 |
EP2216023A4 (en) | 2007-11-15 | 2013-03-13 | Takeda Pharmaceutical | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF |
WO2009111004A1 (en) * | 2008-03-04 | 2009-09-11 | Arena Pharmaceuticals, Inc. | Processes for the preparation of intermediates related to the 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine |
EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
PE20110061A1 (es) | 2008-06-12 | 2011-01-31 | Janssen Pharmaceutica Nv | Derivados de diamino-piridina, pirimidina y piridazina como moduladores del receptor h4 de histamina |
WO2009154739A2 (en) * | 2008-06-17 | 2009-12-23 | Duke University | Smoothened receptor modulators |
ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
EP2358200A4 (en) | 2008-11-17 | 2012-05-16 | Merck Sharp & Dohme | BICYCLIC AMINES SUBSTITUTED FOR THE TREATMENT OF DIABETES |
US8952197B2 (en) | 2009-06-18 | 2015-02-10 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-HT2C receptor agonists |
PE20121403A1 (es) * | 2009-06-26 | 2012-11-02 | Sanofi Sa | Nuevas sales de fumarato de un antagonista del receptor de histamina h3 |
WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
US20120220567A1 (en) | 2009-07-23 | 2012-08-30 | Shipps Jr Gerald W | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
US20120253036A1 (en) | 2009-12-11 | 2012-10-04 | Yukinori Nagakura | Agent for treating fibromyalgia |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2011137024A1 (en) | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
US9365539B2 (en) | 2010-05-11 | 2016-06-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
KR20130112848A (ko) | 2010-06-02 | 2013-10-14 | 아레나 파마슈티칼스, 인크. | 5-ht2c 수용체 아고니스트의 제조 방법 |
US9006268B2 (en) | 2010-06-11 | 2015-04-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
PL2585216T3 (pl) * | 2010-06-23 | 2020-06-01 | Johnson Matthey Plc | Kompleksy pi-allilopalladowe i pi-alliloniklowe do zastosowania jako katalizatory w reakcjach sprzęgania węgiel-azot |
CA2808909A1 (en) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Salts of lorcaserin with optically active acids |
CN103347523A (zh) | 2010-09-01 | 2013-10-09 | 艾尼纳制药公司 | 向具有肾损伤的个体给药氯卡色林 |
WO2012030957A2 (en) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Non-hygroscopic salts of 5-ht2c agonists |
KR20180118801A (ko) | 2010-09-01 | 2018-10-31 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 체중 관리에 유용한 5-ht2c 작동제의 변형-방출 투여 형태 |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CA2812061A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
MX337477B (es) * | 2011-02-25 | 2016-03-07 | Yuhan Corp | Derivados de diaminopiridina y procesos para su preparacion. |
EP3243385B1 (en) | 2011-02-25 | 2021-01-13 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
RU2014150494A (ru) * | 2012-05-30 | 2016-07-20 | Ф. Хоффманн-Ля Рош Аг | Пирролидиногетероциклы |
JP2015525782A (ja) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病性三環式化合物 |
BR112015007779A2 (pt) | 2012-10-09 | 2017-07-04 | Arena Pharm Inc | célula de fluxo de permeabilidade e sistema de condutância hidráulica |
DK3007689T3 (en) | 2013-01-10 | 2018-06-14 | Pulmokine Inc | NON-SELECTIVE KINASE INHIBITORS |
CN104994848A (zh) | 2013-02-22 | 2015-10-21 | 默沙东公司 | 抗糖尿病二环化合物 |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
PT3004138T (pt) | 2013-06-05 | 2024-06-18 | Bausch Health Ireland Ltd | Agonistas ultrapuros de guanilato ciclase c, método de produção e utilização dos mesmos |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CA2926793C (en) | 2013-10-11 | 2022-11-22 | Lawrence S. ZISMAN | Spray-dry formulations for treating pulmonary arterial hypertension |
WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
CN107405332A (zh) | 2015-01-06 | 2017-11-28 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病症的方法 |
CA3002551A1 (en) | 2015-06-22 | 2016-12-29 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders |
BR112019008622A2 (pt) | 2016-10-27 | 2019-07-09 | Pulmokine Inc | método para tratar uma condição |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
WO2019131902A1 (ja) | 2017-12-27 | 2019-07-04 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
BR112021017621A2 (pt) * | 2019-03-07 | 2021-11-23 | Arbormentis LLC | Composições e métodos de uso compreendendo substâncias com ações de plasticidade neural administradas em dosagens e formulações não psicodélicas/psicotomiméticas |
CN111704582B (zh) * | 2020-06-23 | 2021-06-11 | 杭州煌森生物科技有限公司 | 一种法匹拉韦及其衍生物的制备方法 |
CN115618396B (zh) * | 2022-11-28 | 2023-04-07 | 云账户技术(天津)有限公司 | 一种数据的加密方法及装置 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL127996C (is) * | 1963-11-19 | |||
US3980781A (en) * | 1966-03-31 | 1976-09-14 | Imperial Chemical Industries Limited | Fungicidal composition and method containing 2-amino-pyrimidines |
GB1165283A (en) * | 1967-01-17 | 1969-09-24 | Science Union & Cie | New Purine Derivatives and processes for prepararing them |
US4166852A (en) * | 1974-08-09 | 1979-09-04 | Produits Chimiques Ugine Kuhlmann | Piperazino-pyrimidines and their use as spasmolytic agents |
FR2281117A2 (fr) | 1974-08-09 | 1976-03-05 | Ugine Kuhlmann | Nouvelles piperazino-pyrimidines utilisables comme medicaments |
US4081542A (en) * | 1975-04-21 | 1978-03-28 | Merck & Co., Inc. | Piperazinylpyrazines |
EG12387A (en) * | 1975-04-21 | 1978-12-31 | Merck & Co Inc | Process for preparing of piperazinyl pyrazines |
FR2311776A1 (fr) * | 1975-05-23 | 1976-12-17 | Sogeras | Diamino-2,4 bromo-5 chloro-6 pyrimidines et procede pour leur preparation |
FI70411C (fi) * | 1980-12-29 | 1986-09-19 | Pfizer | Foerfarande foer framstaellning av nya antihypertensiva 4-amino-6,7-dimetoxi-2-piperazinokinazolin derivat |
HU206337B (en) * | 1988-12-29 | 1992-10-28 | Mitsui Petrochemical Ind | Process for producing pyrimidine derivatives and pharmaceutical compositions |
DE3905364A1 (de) * | 1989-02-22 | 1990-08-23 | Hoechst Ag | Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool |
GB9012592D0 (en) | 1990-06-06 | 1990-07-25 | Smithkline Beecham Intercredit | Compounds |
JPH0665203A (ja) * | 1992-06-25 | 1994-03-08 | Elf Sanofi | ピペラジンのヘテロ環誘導体 |
AU683620B2 (en) * | 1992-09-28 | 1997-11-20 | Pfizer Inc. | Substituted pyrimidines for control of diabetic complications |
EP0723533A1 (en) * | 1993-10-12 | 1996-07-31 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
CN1142817A (zh) * | 1993-10-12 | 1997-02-12 | 杜邦麦克制药有限公司 | 1n-烷基-n-芳基嘧啶胺及其衍生物 |
US5419301A (en) * | 1994-04-14 | 1995-05-30 | Ford Motor Company | Adaptive control of camless valvetrain |
EP0826674A4 (en) | 1995-04-03 | 1998-07-08 | Sumitomo Pharma | EFFECTIVE PYRIMIDINE DERIVATIVES AS PSYCHOTROPE, AND METHOD FOR THE PRODUCTION THEREOF |
US5795905A (en) | 1995-06-06 | 1998-08-18 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
PT791355E (pt) * | 1996-02-29 | 2002-08-30 | Pfizer | Metodo para diminuir os daos associados com a isquemia nos tecidos |
US6326368B1 (en) * | 1996-03-27 | 2001-12-04 | Dupont Pharmaceuticals Company | Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof |
TW440563B (en) * | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
KR100239800B1 (ko) * | 1996-11-28 | 2000-03-02 | 손경식 | 4,5-디아미노 피리미딘 유도체 및 이의 제조방법 |
DE19710435A1 (de) * | 1997-03-13 | 1998-09-17 | Hoechst Ag | Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen |
US6440965B1 (en) * | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
AU1738900A (en) | 1998-11-19 | 2000-06-05 | Nortran Pharmaceuticals Inc. | Serotonin ligands as pro-erectile compounds |
GB9902047D0 (en) | 1999-01-29 | 1999-03-17 | Cerebrus Ltd | Chemical compounds XI |
CA2374898C (en) | 1999-05-21 | 2009-12-08 | Biovitrum Ab | Pyrazinyl-piperazine compounds, their use and preparation |
SE0002754D0 (sv) | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New pharmaceutical combination formulation and method of treatment with the combination |
SE0004245D0 (sv) * | 2000-11-20 | 2000-11-20 | Pharmacia Ab | Novel compounds and their use |
PL361690A1 (en) | 2000-11-20 | 2004-10-04 | Biovitrum Ab | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor |
EP1337518B1 (en) | 2000-11-20 | 2009-06-17 | Biovitrum AB (publ) | Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor |
-
2002
- 2002-05-28 US US10/156,884 patent/US6825198B2/en not_active Expired - Fee Related
- 2002-06-05 US US10/163,881 patent/US6894050B2/en not_active Expired - Fee Related
- 2002-06-05 DO DO2002000412A patent/DOP2002000412A/es unknown
- 2002-06-14 GT GT200200120A patent/GT200200120A/es unknown
- 2002-06-17 CZ CZ20033431A patent/CZ20033431A3/cs unknown
- 2002-06-17 KR KR1020037016699A patent/KR100566854B1/ko not_active IP Right Cessation
- 2002-06-17 AU AU2002309173A patent/AU2002309173B2/en not_active Ceased
- 2002-06-17 BR BR0210471-7A patent/BR0210471A/pt not_active IP Right Cessation
- 2002-06-17 GE GE5389A patent/GEP20053655B/en unknown
- 2002-06-17 EE EEP200400026A patent/EE200400026A/xx unknown
- 2002-06-17 JP JP2003507068A patent/JP2004534823A/ja not_active Withdrawn
- 2002-06-17 HU HU0400251A patent/HUP0400251A3/hu unknown
- 2002-06-17 KR KR10-2003-7016704A patent/KR20040010767A/ko not_active Application Discontinuation
- 2002-06-17 MX MXPA03011940A patent/MXPA03011940A/es active IP Right Grant
- 2002-06-17 SK SK1567-2003A patent/SK15672003A3/sk unknown
- 2002-06-17 PL PL02367777A patent/PL367777A1/xx not_active Application Discontinuation
- 2002-06-17 NZ NZ529542A patent/NZ529542A/en unknown
- 2002-06-17 CA CA002450491A patent/CA2450491A1/en not_active Abandoned
- 2002-06-17 MX MXPA03011941A patent/MXPA03011941A/es unknown
- 2002-06-17 EE EEP200400025A patent/EE200400025A/xx unknown
- 2002-06-17 YU YU95303A patent/YU95303A/sh unknown
- 2002-06-17 TN TNPCT/IB2002/002261A patent/TNSN03143A1/fr unknown
- 2002-06-17 WO PCT/IB2002/002293 patent/WO2003000666A1/en not_active Application Discontinuation
- 2002-06-17 CN CNA028137345A patent/CN1630645A/zh active Pending
- 2002-06-17 EA EA200301215A patent/EA007183B1/ru not_active IP Right Cessation
- 2002-06-17 WO PCT/IB2002/002261 patent/WO2003000663A1/en active IP Right Grant
- 2002-06-17 EA EA200301213A patent/EA200301213A1/ru unknown
- 2002-06-17 HU HU0400249A patent/HUP0400249A3/hu unknown
- 2002-06-17 BR BR0210503-9A patent/BR0210503A/pt not_active IP Right Cessation
- 2002-06-17 JP JP2003507071A patent/JP2005501821A/ja not_active Abandoned
- 2002-06-17 CA CA002455292A patent/CA2455292A1/en not_active Abandoned
- 2002-06-17 IL IL15880702A patent/IL158807A0/xx unknown
- 2002-06-17 SK SK1571-2003A patent/SK15712003A3/sk not_active Application Discontinuation
- 2002-06-17 UA UA20031211976A patent/UA74443C2/uk unknown
- 2002-06-17 EP EP02735869A patent/EP1401820A1/en not_active Withdrawn
- 2002-06-17 PL PL02367746A patent/PL367746A1/xx not_active Application Discontinuation
- 2002-06-17 OA OA1200300330A patent/OA12629A/en unknown
- 2002-06-17 OA OA1200300319A patent/OA12621A/en unknown
- 2002-06-17 IL IL15880802A patent/IL158808A0/xx unknown
- 2002-06-17 CN CNA028125541A patent/CN1745074A/zh active Pending
- 2002-06-17 CZ CZ20033508A patent/CZ20033508A3/cs unknown
- 2002-06-17 TN TNPCT/IB2002/002293A patent/TNSN03142A1/fr unknown
- 2002-06-17 EP EP02735853A patent/EP1401819A1/en not_active Withdrawn
- 2002-06-19 PE PE2002000529A patent/PE20030268A1/es not_active Application Discontinuation
- 2002-06-19 AR ARP020102299A patent/AR036095A1/es unknown
- 2002-06-20 SV SV2002001102A patent/SV2003001102A/es not_active Application Discontinuation
- 2002-06-20 AP APAP/P/2002/002561A patent/AP2002002561A0/en unknown
- 2002-06-20 UY UY27343A patent/UY27343A1/es not_active Application Discontinuation
- 2002-06-21 PA PA20028548901A patent/PA8548901A1/es unknown
-
2003
- 2003-11-13 ZA ZA200308843A patent/ZA200308843B/en unknown
- 2003-11-13 ZA ZA200308842A patent/ZA200308842B/en unknown
- 2003-11-17 IS IS7040A patent/IS7040A/is unknown
- 2003-11-17 IS IS7041A patent/IS7041A/is unknown
- 2003-11-25 CR CR7168A patent/CR7168A/es not_active Application Discontinuation
- 2003-12-08 EC EC2003004881A patent/ECSP034881A/es unknown
- 2003-12-09 EC EC2003004884A patent/ECSP034884A/es unknown
- 2003-12-10 MA MA27431A patent/MA27035A1/fr unknown
- 2003-12-10 MA MA27432A patent/MA27036A1/fr unknown
- 2003-12-16 HR HR20031042A patent/HRP20031042A2/hr not_active Application Discontinuation
- 2003-12-19 NO NO20035697A patent/NO20035697D0/no not_active Application Discontinuation
- 2003-12-19 NO NO20035698A patent/NO20035698L/no not_active Application Discontinuation
- 2003-12-22 BG BG108495A patent/BG108495A/xx unknown
- 2003-12-22 BG BG108491A patent/BG108491A/xx unknown
-
2004
- 2004-08-19 US US10/922,198 patent/US20050020604A1/en not_active Abandoned
- 2004-08-19 US US10/922,058 patent/US20050090503A1/en not_active Abandoned
- 2004-09-16 US US10/942,346 patent/US20050054656A1/en not_active Abandoned
- 2004-09-16 US US10/942,345 patent/US6995159B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS7041A (is) | 5-HT viðtakabindlar og notkun þeirra | |
IS8032A (is) | Kannabinóíð viðtakabindlar og notkun þeirra | |
DK1417175T3 (da) | Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf | |
IS8054A (is) | Kannabinóíð viðtaka bindlar og notkun þeirra | |
IS8137A (is) | Kannabinóíð viðtaka bindlar og notkun þeirra | |
IS6934A (is) | Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar | |
NO20041975L (no) | Bicyklisk oksopyridin og oksopyrimidinderivater | |
DK1390389T3 (da) | Cripto-blokerende antistoffer og anvendelser deraf | |
IS6802A (is) | 3-arýlindólafleiður og notkun þeirra sem CB2 viðtakagerandefni | |
NO20034159L (no) | Östrogen-gestagen-kombinasjonspreparat og anvendelse derav | |
DK1429769T3 (da) | Nye formuleringer og anvendelse deraf | |
NO20033854D0 (no) | N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse | |
EE200300339A (et) | Helicobacter pylory uudsed retseptorid ja nende kasutamine | |
DE60239866D1 (de) | Fischer-tropsch-verfahren | |
NO20044106L (no) | Omkonstruerte baculoviruser og anvendelse derav | |
NO20023144D0 (no) | Kompleks omfattende OCIF og polysakkarid | |
NO20042500L (no) | Chemokin-reseptorantagonister og metoder for anvendelse derav | |
ATE299873T1 (de) | Substituierte c-furan-2-yl-methylamin- und c- thiophen-2-yl-methylamin-derivate | |
DK1429770T3 (da) | Nye formuleringer og anvendelse deraf | |
NO20033919D0 (no) | Ny anvendelse | |
NO20053898D0 (no) | Use and proceeding at footballshoes | |
DE60219418D1 (de) | Silanylphenole und -naphthole | |
SE0104404D0 (sv) | New methods and use | |
SE0100798D0 (sv) | New use | |
SE0103291D0 (sv) | New use |